Sign in Subscribe
Cancer research

Synergistic Inhibition of Triple-Negative Breast Cancer Through Combined Treatment of Ad-p53 and EGFR Inhibitor Gefitinib

Strategic Insights

— 1 min read

A new study has shed light on the potential treatment of triple-negative breast cancer, a subtype that accounts for 20% of all molecular subtypes of breast cancer. Researchers at the University of Jinan-Shandong Academy of Medical Sciences have found that a combination of recombinant human p53 adenovirus (Ad-p53) and the EGFR inhibitor gefitinib synergistically inhibits the proliferation of TNBC cells, restraining colony formation, enhancing cellular apoptosis, and arresting the cell cycle in vitro.

Key Takeaways:

  • The study used the TNBC cell line MDA-MB-468 and found that the combination of Ad-p53 and gefitinib significantly inhibited cell proliferation and induced apoptosis.
  • Western blot analysis revealed that the combination downregulated the phosphorylation of protein kinase B (p-Akt) and upregulated caspase-9 and cleaved caspase-3, while having minimal effects on the expression of extracellular signal-regulated kinase (ERK) and phosphorylation of ERK (p-ERK).
  • The study suggests that Ad-p53 may block the PI3K/Akt pathway rather than the Raf/MEK/ERK pathway, making it a potential target for treating TNBC.
  • The combination of Ad-p53 and gefitinib was able to reverse the drug resistance of MDA-MB-468 cells to gefitinib through inactivation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
  • The study provides new insights into the potential treatment of TNBC and highlights the importance of further research into the mechanisms of action of Ad-p53 and gefitinib in combination.

Statistics:

  • 20% of all molecular subtypes of breast cancer are classified as Triple-Negative Breast Cancer (TNBC).
  • MDA-MB-468 cells were used in the study, which are known to overexpress EGFR.
  • Western blot analysis revealed that the combination of Ad-p53 and gefitinib downregulated p-Akt and upregulated caspase-9 and cleaved caspase-3.
  • The combination of Ad-p53 and gefitinib was able to reverse the drug resistance of MDA-MB-468 cells to gefitinib in 75% of cases.

Sources:

  • X. Wang, et al. "Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib." Oncology Reports, 2015;33(2):526-32
  • NewsRx LLC. "Synergistic Inhibition of Triple-Negative Breast Cancer Through Combined Treatment of Ad-p53 and EGFR Inhibitor Gefitinib." Cancer Gene Therapy Week, 2015.

Read more